- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 932318, 11 pages
A Full GMP Process to Select and Amplify Epitope-Specific T Lymphocytes for Adoptive Immunotherapy of Metastatic Melanoma
1Inserm, U892, 44000 Nantes, France
2Université de Nantes, 44000 Nantes, France
3CNRS, UMR 6299, 44000 Nantes, France
4Unit of Cell and Gene Therapy, CHU Nantes, 44000 Nantes, France
5Unit of Skin Cancer, CHU Nantes, 44000 Nantes, France
Received 18 July 2013; Revised 27 August 2013; Accepted 27 August 2013
Academic Editor: John Maher
Copyright © 2013 N. Labarriere et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- C. M. Rooney, M. A. Roskrow, N. Suzuki, C. Y. C. Ng, M. K. Brenner, and H. Heslop, “Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells,” Annals of Oncology, vol. 9, no. 5, pp. S129–S132, 1998.
- B. Dréno, J.-M. Nguyen, A. Khammari et al., “Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma,” Cancer Immunology, Immunotherapy, vol. 51, no. 10, pp. 539–546, 2002.
- A. Khammari, J.-M. Nguyen, M. C. Pandolfino et al., “Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma,” Cancer Immunology, Immunotherapy, vol. 56, no. 11, pp. 1853–1860, 2007.
- N. Labarrière, M.-C. Pandolfino, N. Gervois et al., “Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients,” Cancer Immunology, Immunotherapy, vol. 51, no. 10, pp. 532–538, 2002.
- A. Khammari, N. Labarrière, V. Vignard et al., “Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones,” The Journal of Investigative Dermatology, vol. 129, no. 12, pp. 2835–2842, 2009.
- V. Vignard, B. Lemercier, A. Lim et al., “Adoptive transfer of tumor-reactive melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional melan-A-specific T cells,” Journal of Immunology, vol. 175, no. 7, pp. 4797–4805, 2005.
- C. Yee, J. A. Thompson, D. Byrd et al., “Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16168–16173, 2002.
- C. Barrow, J. Browning, D. MacGregor et al., “Tumor antigen expression in melanoma varies according to antigen and stage,” Clinical Cancer Research, vol. 12, no. 3, pp. 764–771, 2006.
- Y. Godet, A. Moreau-Aubry, Y. Guilloux et al., “MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency,” Journal of Experimental Medicine, vol. 205, no. 11, pp. 2673–2682, 2008.
- P. G. Coulie, V. Brichard, A. Van Pel et al., “A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas,” Journal of Experimental Medicine, vol. 180, no. 1, pp. 35–42, 1994.
- Y. Kawakami, S. Eliyahu, C. H. Delgado et al., “Identification of a human melanoma antigen recognized by tumor- infiltrating lymphocytes associated with in vivo tumor rejection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 14, pp. 6458–6462, 1994.
- Y. Godet, J. Desfrançois, V. Vignard et al., “Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy,” European Journal of Immunology, vol. 40, no. 6, pp. 1786–1794, 2010.
- M. J. Pittet, A. Zippelius, D. Valmori, D. E. Speiser, J.-C. Cerottini, and P. Romero, “Melan-A/MART-1-specific CD8 T cells: from thymus to tumor,” Trends in Immunology, vol. 23, no. 7, pp. 325–328, 2002.
- A. Zippelius, M. J. Pittet, P. Batard et al., “Thymic selection generates a large T cell pool recognizing a self-peptide in humans,” Journal of Experimental Medicine, vol. 195, no. 4, pp. 485–494, 2002.
- H. Benlalam, V. Vignard, A. Khammari et al., “Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients,” Cancer Immunology, Immunotherapy, vol. 56, no. 4, pp. 515–526, 2007.
- R. Bouquié, A. Bonnin, K. Bernardeau et al., “A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes,” Cancer Immunology, Immunotherapy, vol. 58, no. 4, pp. 553–566, 2009.
- N. Labarrière, N. Gervois, A. Bonnin, R. Bouquié, F. Jotereau, and F. Lang, “PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting,” Cancer Immunology, Immunotherapy, vol. 57, no. 2, pp. 185–195, 2008.
- M. Bodinier, M.-A. Peyrat, C. Tournay et al., “Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding,” Nature Medicine, vol. 6, no. 6, pp. 707–710, 2000.
- D. Valmori, J.-F. Fonteneau, C. M. Lizana et al., “Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues,” Journal of Immunology, vol. 160, no. 4, pp. 1750–1758, 1998.
- N. Gervois, N. Labarriere, S. Le Guiner et al., “High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells,” Clinical Cancer Research, vol. 6, no. 4, pp. 1459–1467, 2000.
- G. H. S. Richter, A. Mollweide, K. Hanewinkel, C. Zobywalski, and S. Burdach, “CD25 blockade protects T cells from activation-induced cell death (AICD) via maintenance of TOSO expression,” Scandinavian Journal of Immunology, vol. 70, no. 3, pp. 206–215, 2009.
- V. Decot, L. Voillard, V. Latger-Cannard et al., “Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression,” Experimental Hematology, vol. 38, no. 5, pp. 351–362, 2010.
- J. D. Goldstein, L. Perol, B. Zaragoza, A. Baeyens, G. Marodon, and E. Piaggio, “Role of cytokines in thymus- versus peripherally derived-regulatory T cell differentiation and function,” Frontiers in Immunology, vol. 4, article 155, 2013.
- A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger, and R. Andreesen, “Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma,” Journal of Clinical Oncology, vol. 24, no. 31, pp. 5060–5069, 2006.
- N. Meidenbauer, J. Marienhagen, M. Laumer et al., “Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients,” Journal of Immunology, vol. 170, no. 4, pp. 2161–2169, 2003.
- B. Palermo, R. Campanelli, S. Garbelli et al., “Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis,” Melanoma Research, vol. 12, no. 5, pp. 491–498, 2002.
- P. Filipazzi, L. Pilla, L. Mariani et al., “Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides,” Clinical Cancer Research, vol. 18, pp. 6485–6496, 2012.
- D. Valmori, F. Lévy, I. Miconnet et al., “Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-A peptide analogue,” Journal of Immunology, vol. 164, no. 2, pp. 1125–1131, 2000.